Literature DB >> 11594898

Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease.

A D Federman1, A S Adams, D Ross-Degnan, S B Soumerai, J Z Ayanian.   

Abstract

CONTEXT: Cost-sharing in US prescription drug coverage plans for elderly persons varies widely. Evaluation of prescription drug use among elderly persons by type of health insurance could provide useful information for designing a Medicare drug program.
OBJECTIVE: To determine use of effective cardiovascular drugs among elderly persons with coronary heart disease (CHD) by type of health insurance. DESIGN, SETTING, AND PATIENTS: Cross-sectional evaluation of 1908 community-dwelling adults, aged 66 years or older, with a history of CHD or myocardial infarction from the 1997 Medicare Current Beneficiary Survey, a nationally representative sample of Medicare beneficiaries. MAIN OUTCOME MEASURES: Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), beta-blockers, and nitrates, and out-of-pocket expenditures for prescription drugs, stratified by type of health insurance: Medicare without drug coverage (Medicare only or self-purchased supplemental insurance) or with drug coverage (Medicaid, other public program, Medigap, health maintenance organization, or employer-sponsored plan).
RESULTS: Statin use ranged from 4.1% in Medicare patients with no drug coverage to 27.4% in patients with employer-sponsored drug coverage (P<.001). Less variation between these 2 types occurred for beta-blockers (20.7% vs 36.1%; P =.003) and nitrates (20.4% vs 38.0%; P =.005). In multivariate analyses, statin use remained significantly lower for patients with Medicare only (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.05-0.49) and beta-blocker use was lower for Medicaid patients (OR, 0.55; 95% CI, 0.34-0.88) vs those with employer-sponsored coverage. Nitrate use occurred less frequently in persons lacking drug coverage (patients with Medicare only, P =.049; patients with supplemental insurance without drug coverage, P =.03). Patients with Medicare only spent a much larger fraction of income on prescription drugs compared with those with employer-sponsored drug coverage (7.9% vs 1.7%; adjusted P<.001).
CONCLUSION: Elderly Medicare beneficiaries with CHD who lack drug coverage have disproportionately large drug expenditures and lower use rates of statins, a class of relatively expensive drugs that improve survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594898     DOI: 10.1001/jama.286.14.1732

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  40 in total

1.  Costs and benefits of free medications after myocardial infarction.

Authors:  Irfan A Dhalla; Monique A Smith; Niteesh K Choudhry; Avram E Denburg
Journal:  Healthc Policy       Date:  2009-11

2.  Use of guideline-recommended therapies for heart failure in the Medicare population.

Authors:  Lisa D DiMartino; Alisa M Shea; Adrian F Hernandez; Lesley H Curtis
Journal:  Clin Cardiol       Date:  2010-07       Impact factor: 2.882

3.  Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia.

Authors:  Stephen D Persell; Donald M Lloyd-Jones; David W Baker
Journal:  J Gen Intern Med       Date:  2005-12-22       Impact factor: 5.128

Review 4.  Medical paternalism and expensive unsubsidised drugs.

Authors:  Michael Jefford; Julian Savulescu; Jacqui Thomson; Penelope Schofield; Linda Mileshkin; Emilia Agalianos; John Zalcberg
Journal:  BMJ       Date:  2005-11-05

5.  Was there compression of disability for older Americans from 1992 to 2003?

Authors:  Liming Cai; James Lubitz
Journal:  Demography       Date:  2007-08

6.  Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Authors:  Niteesh K Choudhry; Amanda R Patrick; Elliott M Antman; Jerry Avorn; William H Shrank
Journal:  Circulation       Date:  2008-02-19       Impact factor: 29.690

7.  Efficacy of alternate day versus daily dosing of rosuvastatin.

Authors:  Daisy Dulay; Stephen A LaHaye; Karen A Lahey; Andrew G Day
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

8.  Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries.

Authors:  Supriya Gupta Mohile; Ying Xian; William Dale; Susan G Fisher; Miriam Rodin; Gary R Morrow; Alfred Neugut; William Hall
Journal:  J Natl Cancer Inst       Date:  2009-07-28       Impact factor: 13.506

Review 9.  Cost of pharmacological care of the elderly: implications for healthcare resources.

Authors:  Ciaran O'Neill; Carmel M Hughes; James Jamison; Anna Schweizer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Barriers to patient-physician communication about out-of-pocket costs.

Authors:  G Caleb Alexander; Lawrence P Casalino; Chien-Wen Tseng; Diane McFadden; David O Meltzer
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.